Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-07
1999-11-30
Hauda, Karen M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435375, 435 691, 4353201, 536 231, 536 245, A61K 4800, C12N 1563, C12N 1511, C12N 1509
Patent
active
059943157
ABSTRACT:
An oligonucleotide which is antisense to a mRNA encoding a polypeptide involved in airway disease(s) contains up to three adenosines per every 21 nucleotide a method of treating airway disease in a subject in need of such treatment comprises topically administering to the subject an antisense oligonucleotide in an amount effective to treat the airway disease, where the antisense oligonucleotide is essentially free of adenosine. Pharmaceutical formulations are also disclosed.
REFERENCES:
patent: 5087617 (1992-02-01), Smith
patent: 5245022 (1993-09-01), Weis et al.
patent: 5248671 (1993-09-01), Smith
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5521291 (1996-05-01), Curiel et al.
J. Milligan et al.; Current Concepts in Antisense Drug Design. J. Med. Chem. 36(14): 1923-1937 (1993).
S. Ali et al.; Adenosine-induced bronchoconstriction in a allergic rabbit model:antagonism by theophylline aerosol. Agents Actions 37:165-176 (1992).
S. Ali et al.; Modification of allergen-induced airway obstruction and bronchial hyperresponsiveness in the allergic rabbit by theophylline aerosol. Agents Actions 37:168-170 (1992).
S. Ali et al.; Adenosine-Induced Bronchoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Adenosine A.sub.1 Receptor. J. Pharmacol. Exp. Therapeu. 268:1328-1334 (1994).
S. Ali et al.; Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model. Am. J. Physiol. 266:L271-277 (1994).
Nyce, J.W., "Respirable Antisense Oligonucleotides as Novel Therapeutic Agents for Asthma and Other Pulmonary Diseases", Exp. Opin. Invest. Drugs, 6(9): 1-7, (1997).
Nyce, J.W. et al., "DNA Antisense Therapy for Asthma in an Animal Model", Nature, 385(20): 721-725, (1997).
Akhter, S. et al., "In Vivo Studies with Antisense Oligonucleotides", Trends in Pharmacol. Sciences, 18: 12-18, (1997).
Webb, A. et al., "BCL-2 Antisense Therapy in Patients with Non-Hodgkin Lymphoma", Lancet, 349(9059): 1137-41, (1997).
Yazaki, T. et al., "Treatment of Glioblastoma U-87 by Systemic Administration of an Antisense Protein Kinase C-Alpha Phosphorothioate Oligodeoxynucleotide", Molecular Pharmacol., 50(2): 236-242, (1996).
Farmer, S.G. et al., "Adenosine Receptor-mediated Contraction and Relaxation of Guinea-pig Isolated Tracheal Smooth Muscle: Effects of Adenosine Antagonists", Br. J. Pharmacol., 95: 371-378 (1988).
Marquardt, D.L. et al., "Aminophylline Exposure Alters Mouse Bone Marrow-derived Mast Cell Adenosine Responsiveness", J. Allergy Clin Immunol. 78: 462-469, (1986).
Simpson, R. U. et al, "Antisense oligonucleotide targeting against protein kinase C beta and C beta II block 1,25 -(OH)- 2D3- induced differentiation", J. Biol. Chem. 273(31):19587-19591 (1998).
Chen, CC et al, "Protein kinase Ccta mediates LPS-induced nitric oxide synthesis expression", J. Biol. Chem. 273(31): 19424-19430 (1998).
Glukhov, A. I., et al., "Inhibition of telomerase activity of melanoma cells in vitro by antisense oligodeoxynucleotides", Biochem. Biophys. Res. Commun. 248(2):.368-371 (1998).
Banasiak, K. J. and Haddard G. G., "Hypoxia-induced apoptosis: effect of hypoxia severity and role of p53 in neuronal cell death (Antisense to p53)", Brain Res. 797(2): 295-304 (1998).
Lehenkaru P et al, "Carbonic anhydrase II plays a major role in osteoclast differentiation (antisense to carbonic anhydrase II)", Exp Cell Res 242(1):128-137 (1998).
Dooley NP et al, "Apoptosis is induced in glioma cells by antisense oligonucleotide to protein kinase C alpha", Neuroreport 9(8):1727-1733 (1998).
Kondo S et al, Antisense telomerase treatment: induction of distinct pathways, apoptosis and differentiation, FASEB J. 129100:801-811 (1998).
Alahari SK et al, "Novel chemically modified oligonucleotide provide potent inhibition of p-glycoprotein (an ATPase that serves as a drug efflux pump)", J. Pharmacol. Exp. Therapeut. 286(1): 419-428 (1998).
Dennis J. U., et al, "Human melanoma metastases is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C alpha", Cancer Lett. 128(1): 65-70 (1998).
Haeckel C., et al, "Antisense oligonucleotide inhibit urokinase", Int. J. Cancer 77(1): 153-160 (1998).
Kobayashi S. et al, "Transcription factor NF-E2 is essential for the polyploidization of Meg-J", Biochem. Biophys. Res. Commun. 247(1): 65-69 (1998).
Bennett, M.R. (1995). J. Drug Dev. Clin. Pract. 7, 225-235.
Heidenreich, O. et al (1995) Molecular Medicine Today 1, 128-133.
Gura, T. (1995) Science 270, 575-577.
De Mesmaeker, A et al (1995). Acc. Chem. Res. 28, 366-374.
Monia, B. P. et al (1992). The Journal of Biological Chemistry 267, 19954-19962.
Knight, V. et. al. (1988) Eur. Journal of Clinical Microbiology and Protections Diseases 7, 721-31 Abstract only.
Schreier, H. (1994). Pharmaceutica Acta Helvetiae 68, 145-59 Abstract only.
Mao, L. et al (1994). Circulation 90 (4 Part 2), I474. Abstract only.
Metzger W. James
Nyce Jonathan W.
Amzel Viviana
East Carolina University
Hauda Karen M.
LandOfFree
Low adenosine agent, composition, kit and method for treatment o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Low adenosine agent, composition, kit and method for treatment o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low adenosine agent, composition, kit and method for treatment o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1672682